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EVIDENCE FROM A RETROSPECTIVE STUDY IN CANADA, AUSTRALIA, AND
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OBJECTIVES: To evaluate treatment and response patterns among patients with
chronic myeloid leukemia (CML) in Canada, Australia, and South Korea (S.Korea).
METHODS:Oncologists and hematologists in Australia (N31), Canada (N28), and
South Korea (N34) abstracted medical records of adults with CML between 1/1/
2005 and 9/30/2010. Patient selection criteria included: chronic phase at diagnosis,
either Ph or BCR-ABL, received 1st-line imatinib, and had not participated in a
clinical trial. A subset received 2nd-line therapy with nilotinib or dasatinib. Rates of
complete hematological response (CHR) at 3 months, complete cytogenetic re-
sponse (CCyR) at 12 months, and complete or major molecular response (CMR/
MMR) at 18 months were assessed, stratified by 1st- and 2nd-line therapy. RESULTS:
Data on 610 patients (200/country) were collected. Patients’ mean age was 57
years and 59% were male. Patients received 1st-line therapy for 23 months on
average (range: 16 [Canada] to 27 [S.Korea]). Among patients on 1st-line therapy,
78% had CHR at 3 months of treatment (67 [Australia] to 86 [Canada]), 48% had CCyR
at 12 months (range: 42% [Australia] to 60% [S.Korea]), and 70% had CMR/MMR at 18
months (67 [S.Korea] to 77 [Australia]). Approximately 10% of patients (7% [Canada]
to 14% [Australia]) had dose escalation to a median dose of 600mg. Twenty-two
percent of patients discontinued imatinib (17% [S.Korea] to 27% [Australia]). Among
those who discontinued, the most common reason was intolerance in Australia
(60%) and Canada (37%), and other/no response in S.Korea (25%). Eighty-seven
patients had 2nd-line treatment (68 dasatanib, 19 nilotinib). S.Korea had a greater
proportion of 2nd-line nilotinib use (41%) than Australia (22%) and Canada (12%),
and the mean time to 2nd-line therapy was 22 months post-diagnosis.
CONCLUSIONS: This study further illustrates cross-country variations in CML
treatment and response patterns, and emphasizes the need to understand CML
populations in individual countries.
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A POPULATION-BASED PREDICTION OF BREAST CANCER IN RUSSIAN
FEDERATION: ANALYSIS HER2-STATUS GROUPS FOR TARGET TREATMENT
Ryazhenov VV1, Gorokhova SG1, Frank G2, Zavalishina L2
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OBJECTIVES: The significance of state-funded cancer treatment programs, includ-
ing targeted breast cancer medication, makes the prediction of incidence dynamics
very important. Therefore, we have made an attempt predict to indices of breast
cancer among the Russian population up to the year 2020, provided that HER2-
status groups will be identified. METHODS: Basing on the analysis of dynamics of
prevalence, incidence and the outcomes of breast cancer in Russia, national statis-
tics data, and HERA study results, we have developed a dynamic diagnostic-related
model for breast cancer, in which the patients were grouped according to clinical
settings and HER2-status. RESULTS: We have determined that the annual increase
of incidence and prevalence in Russia is 2.25% and3.4%, respectively; the share of
initial breast cancer is 18%; 35% patients were diagnosed breast cancer of III and IV
stages. Taking this as a constant, we have predicted the absolute prevalence in 2015
as 596 661, and 702 533 patients in 2020 Our prediction of the number of patients
with HER2 hyper-expression for the period up to 2015 is based on the assumption
that the average expected prevalence of HER2 hyper-expression will be 15%.
Based on the above mentioned indices, the prevalence of HER2 breast cancer will
be 89 499 patients by the year 2015, while the annual incidence of HER2 initial
breast cancer will amount to 7 958 patients. CONCLUSIONS:A growing tendency of
prevalence and incidence of breast cancer in Russia has been identified; this will
require additional expenditure for the treatment of such patients, including target
therapy (e.g., trastuzumab).
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GEOGRAPHIC VARIATION ASSOCIATED WITH COLORECTAL CANCER
PREVALENCE IN THE UNITED STATES
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OBJECTIVES: To examine the geographic variations associated with the annual
prevalence of colorectal cancer in the U.S. veteran population. METHODS: The
study sample was based on an analysis of the Veterans Health Administration
(VHA) Medical SAS datasets from 2009 through 2011. All patients diagnosed with
colorectal cancer throughout the study period were identified using International
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis
codes 153.xx and 154.xx. Descriptive statistical analyses were performed using SAS
v9.3 software. RESULTS: Washington DC and Puerto Rico held prevalence rates
either at or above 0.6% throughout the 3-year study period, while Alaska and Utah
maintained prevalence values below 0.3%. Although 12 states (including Washing-
ton DC) showed a decrease in colorectal cancer prevalence from 2009 to 2011, a
progressively increasing prevalence of the disease was observed in Ohio (2009:
0.596%; 2010: 0.597%; 2011: 0.602%), Guam (2009: 0.181%; 2010: 0.224%; 2011:
0.240%), and Alaska (2009: 0.219%; 2010: 0.235%; 2011: 0.252%). Two out of the three
states/territories with progressively increasing prevalence were in the lowest risk
category (less than 0.3%). CONCLUSIONS: U.S. veterans living in Puerto Rico and in
the Southern and Mid-Atlantic regions (including West Virginia, Massachusetts,
Washington DC) had a high regional prevalence pattern of colorectal cancer from
2009 to 2011. The geographic variation in risk areas can help identify important
geographically connected prognostic factors, aid in targeted intervention strate-
gies directed at high risk areas, and generate hypotheses about the underlying
causes of colorectal cancer in the United States and associated territories.
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OBJECTIVES: There is no central registry for patients with multiple myeloma in
Germany and data from regional registries can be biased. Since data from sick
funds are recently available, these were used to compare prevalence, co-morbidi-
ties and treatment rates of multiple myeloma patients with data from cancer
registries. METHODS: Three German statutory health insurances (SHI) with
1.780.000 beneficiaries were analyzed for patients diagnosed with multiple my-
eloma (MM) (ICD-10 C90.0) in 2008-2010. Treatment was identified for outpatients
by prescriptions with ATC Codes L01x (antineoplastic agents) and H02A (cortico-
steroids). Co-morbidities were expressed by Hierarchical Condition Categories.
RESULTS: A total of 746 patients had a confirmed diagnosis of multiple myeloma,
53% female and 47% male. The highest incidence for myeloma was between 65 and
80 years. 35% were hospitalized with no information on treatment. Of the outpa-
tients, 10% received a treatment identified by ATC Code L01x (preparations of par-
enteral chemotherapy not included). Most prominently elevated co-morbidities of
MM patients compared to all other patients aged 55 -85 years were anemia (41% vs.
7%), osteoporosis (41% vs. 18%), renal failure (31% vs. 7%), depression (23% vs. 11%)
and infectious diseases (38% vs. 19 %). A higher rate of patients received dexameth-
asone rather than prednisone (41% vs. 28%). The most frequently used antineoplas-
tic agents identifiable by ATC were lenalidomide (16%), followed by melphalan (6%)
and bortezomib (5%). CONCLUSIONS: The age- and gender adjusted and to the
German population extrapolated prevalence of 34.000 patients was higher than
reported prevalence numbers of 13.500 patients (5-year prevalence with 41% rela-
tive 5 year survival rate). The age distribution is consistent but the gender distri-
bution was slightly different from reported numbers1. Patient shares for mel-
phalan and bortezomib are likely to be underreported because parenteral
preparations were not identifiable. Treatment judged for outpatients revealed a
higher share of patients who received 2nd line treatment for multiple myeloma
rather than a 1st line therapy.
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OBJECTIVES:Growing body evidence suggests that statins may decrease the risk of
cancers. However, available evidence on breast cancer is conflicting. We therefore
examined the association between statin use and risk of breast cancer by conduct-
ing a detailed meta-analysis of all observational studies published regarding this
subject. METHODS: PubMed database and bibliographies of retrieved articles were
searched for epidemiological studies published up to January 2012, investigating
the relationship between statin use and breast cancer. Before meta-analysis, the
studies were evaluated for publication bias and heterogeneity. Pooled relative risk
(RR) and 95% confidence interval (CI) was calculated using random-effects model
(DerSimonian and Laird method). Subgroup analyses, sensitivity analyses and cu-
mulative meta-analysis were also performed. RESULTS:A total of 24 (13 cohort and
11 case-control) studies involving more than 2.4 million participants and 76,759
breast cancer cases contributed to this analysis. We found no evidence of publica-
tion bias and evidence of heterogeneity among the studies. Statin use and also
long-term statin use did not significantly affect breast cancer risk (RR 0.99; 95% CI
 0.94-1.04; P 0.69 and RR 1.03; 95% CI 0.96-1.11; P 0.42, respectively). When
the analysis was stratified into subgroups, there was no evidence that study design,
confounder’s adjustments and previous meta-analysis substantially influenced
the effect estimates. Sensitivity analyses confirmed the stability of our results.
Cumulative meta-analysis showed a change in trend of reporting risk of breast
cancer from positive to negative in statin users between 1993 and 2011.
CONCLUSIONS: Our meta-analysis findings do not support the hypothesis that
protective effect of statins against breast cancer. More randomized clinical trials
and observational studies were needed to confirm this association with underlying
biological mechanisms in future.
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INITIAL TREATMENT AND SURVIVAL AMONG ELDERLY PATIENTS WITH
ADVANCED BREAST CANCER BY ESTROGEN RECEPTOR AND PROGESTERONE
RECEPTOR STATUS: AN ANALYSIS OF UNITED STATES NATIONAL REGISTRY
DATA 2000-2009
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OBJECTIVES: To study initial treatment and survival among elderly patients with
newly diagnosed Stage IV breast cancer, by estrogen receptor (ER) and progesterone
receptor (PR) status. METHODS: The linked Surveillance and Epidemiology End
Results-Medicare (SEER-Medicare) database was used for this analysis. We identi-
fied female patients newly diagnosed with Stage IV breast cancer in a SEER registry
between January 2002 and December 2007. Study patients were required to be aged
66 years with no prior history of any other (non-breast) cancer. Patients were
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followed from the date of breast cancer diagnosis through death or December 31,
2009. Patients were identified as having positive (negative) ER or PR status if the
corresponding assay was reported to SEER as positive/elevated (negative/normal).
Demographics, initial treatment (surgery or radiation within 4 months of diagno-
sis), and survival (Kaplan-Meier [KM] survival curves) were evaluated, by ER and PR
status. RESULTS:A total of 3210 female Stage IV BC patients (2,417 [75.3%] ER, and
793 [24.7%] ER-) were identified. Of these, 57.5% were ERPR, 17.8% were ERPR-,
1.4% were ER-PR, and 23.3% were ER-PR-. Age at diagnosis was similar regardless
of ER/PR status (mean [SD] 74-77 [6-7] years). Almost one third of patients had
radiation (30%) and close to half of patients had surgery (43%) in the first 4 months
following diagnosis, with slight variation by ER/PR status. KM survival analyses
suggest that ER patients had significantly higher median survival than ER- pa-
tients (24 months vs. 9 months, P0.01). Median survival was highest for ERPR
patients (25 months) followed by ERPR- (19 months), ER-PR- (9 months), and ER-
PR (7 months). CONCLUSIONS: Among elderly, newly diagnosed Stage IV BC pa-
tients, those with ERPR status had the best survival outcomes. Further studies
of treatment patterns and outcomes by ER and PR status are warranted.
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OBJECTIVES:Although breast cancer is the most common cancer among American
women, study investigating treatment pattern and costs is limited. This study aims
to determine breast cancer treatment patterns and associated health care charges
stratified by initial stage at diagnosis. METHODS: Patients were retrieved from the
University of Utah Huntsman Cancer Institute (HCI) and the Utah Population Da-
tabase. We included female patients with age 18, having 1of breast cancer
ICD9-CM codes, providing informative staging data, and with2 encounters during
the time period. Matching to the HCI Tumor Registry using ICD-0 histology and site
codes validated a primary site breast cancer. Treatment patterns, health care
charges, and overall survival were evaluated. RESULTS:Of 495,523 female patients,
3,109 breast cancers were identified. Mean age was 59.9, 54.6, 53.7, and 56.2 years at
stage I (n1,310), II (n1,220), III (n425), and IV (n154), respectively. The mean
Charlson co-morbidity score (p0.001), the distribution of age (p0.001) and insur-
ance plan types (p0.001) were all significant between the stage groups. Patients
diagnosed at stage I, II, and III received surgery as first treatment, then radiation,
and chemotherapy. Stage IV patients had the highest proportion of patients utiliz-
ing chemotherapy as first treatment, followed decreasing utilization by stages III, II,
and I. The largest annualized charges were incurred in stage IV patients ($68,227),
followed by decreasing charges by stage III ($38,178), II ($23,214), and I ($14,615).
Five year overall survival was 91.15%, 84.43%, 71.76%, and 35.06% for stage I, II, III,
and IV patients, respectively. CONCLUSIONS: Data suggests that our cohort was
generally treated according to NCCN guidelines. Charges increased by stage. Sur-
vival rates decreased by stage and were higher than National Cancer Data Base
statistics. These results provide unique information on the utilization and treat-
ments in breast cancer towards the further conduct of oncology outcomes re-
search.
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OBJECTIVES: Ovarian cancer is the fifth most common cause of cancer death in
women; therefore study investigating treatment patterns, heath care charges and
overall survival is warranted. This study aims to determine ovarian cancer treat-
ment pattern and charges stratified by initial diagnosis stages.METHODS: Patients
were retrieved from linking records in the University of Utah Enterprise Data Ware-
house, the Utah population database, and the Huntsman Cancer Institute Tumor
Registry. We included female patients with age18, having one or more of ovarian
cancer ICD9-CM code (183.0), with informative staging data, and at least 2 encoun-
ters during 1995 to 2010. Treatment patterns, health care charges, and survival
were stratified by stage at initial diagnosis. RESULTS: Of 495,523 female patients,
379 ovarian cancers were identified. Mean age was 51.9, 54.1, 59.3, and 63.5 years at
stage I (n83), II (n31), III (n176), and IV (n89), respectively (p0.001). The mean
Charlson co-morbidity score was significant between the stage groups (p0.001) as
was the distribution of age groups (p0.004). Patients received surgery as first treat-
ment, then chemotherapy, and radiation in all stages. The largest annualized
charges were incurred in stage IV patients ($72,579), followed in decreasing charge
magnitude by stage III ($48,765), II ($50,303), and I ($29,479), respectively. Five year
overall survival was 81.93%, 77.42%, 49.43%, and 15.73% for stage I, II, III, and IV
patients, respectively. CONCLUSIONS: Our findings show that the treatment and
time to treatment in our cohorts mostly follow NCCN guidelines. Patients present-
ing in later stages, as expected, experience reduced survival and increased health
care charges. These results provide unique information on the utilization and
treatments in ovarian cancer towards the further conduct of oncology outcomes
research or economic evaluation. Further study identifying predictors of long term
survival and reduced resource utilization is needed.
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OBJECTIVES: Since the incidence rate of melanoma has more than doubled in the
past 30 years, study investigating treatment patterns and health care charges and
overall survival is warranted. This retrospective study aims to determine mela-
noma treatment patterns, charges, and overall survival stratified by initial stage at
diagnosis. METHODS: Patients were retrieved from linking records in the Univer-
sity of Utah Enterprise Data Warehouse, the Utah Population Database, and the
Huntsman Cancer Institute Tumor Registry during 1995-2010. We included pa-
tients with age 18; having one or more of melanoma ICD9-CM codes; melanoma
associated ICD-0 histology/site codes from the HCI tumor registry with informative
staging data; and had at least 2 encounters during the time period. Treatment
pattern, health care charges and survival were stratified by stage at initial
diagnosis. RESULTS: Of 965,460 patients, 1,463 melanoma patients were identified.
At the time of diagnosis 829 subjects were considered stage I; 254 stage II; 289 stage
III; and 91 stage IV. . The mean Charlson comorbidity score was significantly in-
creased according to the stage group (p0.001) of the patient. Patients diagnosed at
stage I, II, and III received radiation as first treatment, then surgery, followed by
chemotherapy. The most common first treatment for patients with stage IV disease
was chemotherapy. The highest annualized cancer related charges per year, based
on survival days, were incurred by stage IV patients ($80,396), followed by stage III
($33,268), stage II ($21,397), and stage I ($8,327). Five year overall survival rate was
91.44%, 72.44%, 61.59%, and 34.07% for stage I, II, III, and IV patients, respectively.
CONCLUSIONS: This study highlights the distinctive advantages in utilizing com-
prehensive electronic health records by combining in depth clinical data and out-
comes with health care charges, which can be used to assess the cost-effectiveness
of the newly developed melanoma therapeutics.
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OBJECTIVES: The surrogacy of progression-free survival (PFS) for overall survival
(OS) remains a matter of uncertainty in metastatic breast cancer (mBC). Therefore,
the aim of this study was to assess the relationship between PFS and OS in mBC
using a trial-based approach. METHODS: A systematic literature review was per-
formed using the PICO method: Population consisted of women with mBC; Inter-
ventions and Comparators were standard treatments for mBC or best supportive
care; Outcomes of interest were median PFS or TTP and median OS. A correlation
analysis between median PFS and OS was first performed and subgroup analyses
were conducted to explore possible reasons for heterogeneity. Then, the relation-
ship between the treatment effect on PFS and OS was assessed. The treatment
effect on PFS and OS was quantified by the absolute difference of median values.
Linear regression analysis was also conducted to predict the effects of a new anti-
cancer drug on OS on the basis of its effects on PFS. RESULTS: In total, 5041 studies
were identified and 144 fulfilled the eligibility criteria. There was a significant re-
lationship between median PFS and median OS across included trials (r0.428;
p0.01). The correlation coefficient for the treatment effect on PFS and OS was
estimated at 0.427 (p0.01). The linear regression equation was: 	OS -0.088 (95%
CI, -1.347 to 1.172)  1.753 (95% CI, 1.307 to 2.198) * 	PFS, with a proportion of
variation explained (R2) of 0.86. Results of the regression analysis predict that a
difference in median PFS of 5, 10, 15, and 20 months would translate into a differ-
ence in median OS of 8.7, 17.4, 26.2, and 35.0 months respectively. CONCLUSIONS:
The present findings point toward a statistically significant correlation between
PFS and OS in the context of mBC and support the surrogacy of PFS for OS in this
cancer setting.
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RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL
SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
Beauchemin C1, Johnston J2, Lapierre ME1, Aissa F3, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2Manitoba Institute of Cell Biology, Winnipeg,
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OBJECTIVES: Surrogate endpoints, such as progression-free survival (PFS) and
time-to-progression (TTP), are frequently used to evaluate the clinical benefits of
new anticancer drugs. However, the surrogacy of these endpoints for overall sur-
vival (OS) is not validated in all cancer settings. The main objective of this study
was to evaluate the relationship between median PFS/TTP and median OS in the
context of chronic lymphocytic leukemia (CLL) using a trial-based approach.
METHODS: A systematic review of the literature was conducted using the PICO
method: Population consisted of patients with CLL; Interventions and Comparators
(when applicable) were standard therapies for CLL and Outcomes were median
PFS/TTP and median OS. Two independent reviewers screened titles, abstracts,
and full papers for eligibility, and then extracted data from selected studies. Cor-
relation coefficient was calculated to assess the relationship between median PFS/
TTP and median OS. Subgroup correlation analyses were also conducted according
to characteristics of selected studies such as line of treatment and type of treat-
ment under investigation. RESULTS: Among the 1,263 potentially relevant studies
identified by the literature search, 23 articles were included. The mean number of
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